Search

Your search keyword '"Hernandez Jr., Axel"' showing total 10 results
Start Over Author "Hernandez Jr., Axel"
10 results on '"Hernandez Jr., Axel"'

1. Anti-TNF Thioester Glucocorticoid Antibody–Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model.

Author

Marvin, Christopher C., Hobson, Adrian D., McPherson, Michael J., Hayes, Martin E., Patel, Meena V., Schmidt, Diana L., Li, Tongmei, Randolph, John T., Bischoff, Agnieszka K., Fitzgibbons, Julia, Wang, Lu, Hernandez Jr, Axel, Jia, Ying, Goess, Christian A., Bryant, Shaughn H., Mathieu, Suzanne L., and Xu, Jianwen

Published
2024
Full Text
View/download PDF

2. Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates

Author

Marvin, Christopher, primary, Hobson, Adrian, additional, McPherson, Michael, additional, Dunstan, Theresa, additional, Vargo, Thomas, additional, Hayes, Martin, additional, Fettis, Margaret, additional, Bischoff, Agnieszka, additional, Wang, Lu, additional, Hernandez, Jr., Axel, additional, Jia, Ying, additional, Oh, Jason, additional, and Tian, Yu, additional

Published
2023
Full Text
View/download PDF

3. An anti–TNF–glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases.

Author

McPherson, Michael J., Hobson, Adrian D., Hernandez Jr., Axel, Marvin, Christopher C., Waegell, Wendy, Goess, Christian, Oh, Jason Z., Shi, Dan, Hayes, Martin E., Wang, Lu, Schmidt, Diana, Wang, Zhi, Pitney, Victoria, McCarthy, Kimberley, Jia, Ying, Wang, Ce, Kang, Bit Na, Bryant, Shaughn, Mathieu, Suzanne, and Ruzek, Melanie

Subjects
ANTIBODY-drug conjugates, THERAPEUTICS, CONTACT dermatitis, INFLAMMATION, COLLAGEN-induced arthritis
Abstract

Glucocorticoids (GCs) are efficacious drugs used for treating many inflammatory diseases, but the dose and duration of administration are limited because of severe side effects. We therefore sought to identify an approach to selectively target GCs to inflamed tissue. Previous work identified that anti–tumor necrosis factor (TNF) antibodies that bind to transmembrane TNF undergo internalization; therefore, an anti-TNF antibody-drug conjugate (ADC) would be mechanistically similar, where lysosomal catabolism could release a GC receptor modulator (GRM) payload to dampen immune cell activity. Consequently, we have generated an anti–TNF-GRM ADC with the aim of inhibiting pro-inflammatory cytokine production from stimulated human immune cells. In an acute mouse model of contact hypersensitivity, a murine surrogate anti–TNF-GRM ADC inhibited inflammatory responses with minimal effect on systemic GC biomarkers. In addition, in a mouse model of collagen-induced arthritis, single-dose administration of the ADC, delivered at disease onset, was able to completely inhibit arthritis for greater than 30 days, whereas an anti-TNF monoclonal antibody only partially inhibited disease. ADC treatment at the peak of disease was also able to attenuate the arthritic phenotype. Clinical data for a human anti–TNF-GRM ADC (ABBV-3373) from a single ascending dose phase 1 study in healthy volunteers demonstrated antibody-like pharmacokinetic profiles and a lack of impact on serum cortisol concentrations at predicted therapeutic doses. These data suggest that an anti–TNF-GRM ADC may provide improved efficacy beyond anti-TNF alone in immune mediated diseases while minimizing systemic side effects associated with standard GC treatment. Editor's summary: Glucocorticoids are an essential component of the inflammatory disease treatment toolbox, but their side effects limit long-term use. An alternative strategy to dampen inflammatory responses while avoiding side effects is thus urgently needed. Here, McPherson et al. developed an antibody-drug conjugate (ADC) of an anti-TNF antibody and a gluococorticoid receptor modulator (GRM) that, upon internalization in immune cells through transmembrane TNF, resulted in release of the GRM and attenuated inflammatory responses. The authors found that administration of a murine version of the anti–TNF-GRM ADC reduced disease severity in mice with contact hypersensitivity or arthritis better than an anti-TNF antibody alone. Moreover, a phase 1 study of the human anti–TNF-GRM ADC, ABBV-3373, showed favorable pharmacokinetics and safety. Together, these data support continued clinical development ABBV-3373 for immune-mediated inflammatory diseases. —Courtney Malo [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC).

Author

Hobson, Adrian D., Xu, Jianwen, Welch, Dennie S., Marvin, Christopher C., McPherson, Michael J., Gates, Bradley, Liao, Xiaoli, Hollmann, Markus, Gattner, Michael J., Dzeyk, Kristina, Sarvaiya, Hetal, Shenoy, Vikram M., Fettis, Margaret M., Bischoff, Agnieszka K., Wang, Lu, Santora, Ling C., Fitzgibbons, Julia, Salomon, Paulin, Hernandez Jr., Axel, and Jia, Ying

Published
2023
Full Text
View/download PDF

8. Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody-Drug Conjugate Payloads.

Author

Hobson, Adrian D., McPherson, Michael J., Waegell, Wendy, Goess, Christian A., Stoffel, Robert H., Xiang Li, Jian Zhou, Zhongyuan Wang, Yajie Yu, Hernandez Jr., Axel, Bryant, Shaughn H., Mathieu, Suzanne L., Bischoff, Agnieszka K., Fitzgibbons, Julia, Pawlikowska, Martyna, Puthenveetil, Sujiet, Santora, Ling C., Lu Wang, Marvin, Christopher C., and Hayes, Martin E.

Published
2022
Full Text
View/download PDF

9. Correction to "Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody–Drug Conjugate Payloads".

Author

Hobson, Adrian D., McPherson, Michael J., Waegell, Wendy, Goess, Christian A., Stoffel, Robert H., Li, Xiang, Zhou, Jian, Wang, Zhongyuan, Yu, Yajie, Hernandez Jr., Axel, Bryant, Shaughn H., Mathieu, Suzanne L., Bischoff, Agnieszka K., Fitzgibbons, Julia, Pawlikowska, Martyna, Puthenveetil, Sujiet, Santora, Ling C., Wang, Lu, Marvin, Christopher C., and Hayes, Martin E.

Published
2023
Full Text
View/download PDF

10. Correction to "Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate".

Author

Hobson, Adrian D., McPherson, Michael J., Hayes, Martin E., Goess, Christian, Li, Xiang, Zhou, Jian, Wang, Zhongyuan, Yu, Yajie, Yang, Jindong, Sun, Liang, Zhang, Qiang, Qu, Pei, Yang, Shi, Hernandez Jr., Axel, Bryant, Shaughn H., Mathieu, Suzanne L., Bischoff, Agnieszka K., Fitzgibbons, Julia, Santora, Ling C., and Wang, Lu

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results